Glycaemia risk index uncovers distinct glycaemic variability patterns associated with remission status in type 1 diabetes

Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population

(2023) G. Todd Alonso et al.   DIABETES CARE

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

(2023) Christof M. Kazda et al.   DIABETES CARE

Continuous Glucose Monitoring-Based Composite Metrics: A Review and Assessment of Performance in Recent-Onset and Long-Duration Type 1 Diabetes

(2023) Laura E. Donaldson et al.   Diabetes Technology & Therapeutics

Development of Smartphone-Controlled and Microneedle-Based Wearable Continuous Glucose Monitoring System for Home-Care Diabetes Management

(2023) Jian Yang et al.   ACS Sensors

Disparities in Hemoglobin A1c Levels in the First Year After Diagnosis Among Youths With Type 1 Diabetes Offered Continuous Glucose Monitoring

(2023) Ananta Addala et al.   JAMA Network Open

Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients

(2022) Yaxin Wang et al.   Journal of Diabetes Investigation

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

(2022) David C. Klonoff et al.   Journal of diabetes science and technology

Glycemic Variability Patterns Strongly Correlate With Partial Remission Status in Children With Newly Diagnosed Type 1 Diabetes

(2022) Olivier G. Pollé et al.   DIABETES CARE

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

(2022) Gabriel A Gregory et al.   Lancet Diabetes & Endocrinology

Optimal Sampling Duration for Continuous Glucose Monitoring for the Estimation of Glycemia Risk Index

(2022) Viral N. Shah et al.   Diabetes Technology & Therapeutics

Three‐phasic pattern of C‐peptide decline in type 1 diabetes patients with partial remission

(2021) Mei Shi et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Strategies for durable β cell replacement in type 1 diabetes

(2021) Todd M. Brusko et al.   SCIENCE

6. Glycemic Targets: Standards of Medical Care in Diabetes—2022

(2021)   DIABETES CARE

PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes

(2020) Xia Li et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

High residual C-peptide likely contributes to glycemic control in type 1 diabetes

(2020) Michael R. Rickels et al.   JOURNAL OF CLINICAL INVESTIGATION

Establishment of a type 1 diabetes structured education programme suitable for Chinese patients: type 1 diabetes education in lifestyle and self adjustment (TELSA)

(2020) Yuting Xie et al.   BMC Endocrine Disorders

Frequency, clinical characteristics, and determinants of partial remission in type 1 diabetes: Different patterns in children and adults

(2020) Ting Zhong et al.   Journal of Diabetes

Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c

(2019) Anna R. Kahkoska et al.   PEDIATRIC DIABETES

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

(2019) Manuela Battaglia et al.   DIABETES CARE

cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data

(2019) Tim Vigers et al.   PLoS One

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring

(2018) Richard M. Bergenstal et al.   DIABETES CARE

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections

(2017) Roy W. Beck et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes

(2009) H. B. Mortensen et al.   DIABETES CARE